Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Patent Expiry of Blockbuster Drugs and Push for Lower Healthcare Costs Drive Generic Pharmaceuticals Market - New analysis from Frost & Sullivan, U.S. Generic Pharmaceuticals Market Outlook, reveals that this market earned revenues of $24.71 billion in 2006 and estimates this to reach $49.49 billion in 2013
Patent Expiry of Blockbuster Drugs and Push for Lower Healthcare Costs Drive Generic Pharmaceuticals Market

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2007/08/15 - New analysis from Frost & Sullivan, U.S. Generic Pharmaceuticals Market Outlook, reveals that this market earned revenues of $24.71 billion in 2006 and estimates this to reach $49.49 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With several major blockbuster drugs reaching patent expiry, the market for generic pharmaceuticals in the United States is booming and is set to witness significant growth over the next few years. Demand for lower healthcare costs and pressure from payers to increase the use of generics are also major drivers for this market as these drugs are considerably less expensive than the blockbuster drugs developed by branded pharmaceutical companies.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Generic Pharmaceuticals Market Outlook, reveals that this market earned revenues of $24.71 billion in 2006 and estimates this to reach $49.49 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Generic Pharmaceuticals Market Outlook, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

“Patent expiries of blockbuster drugs and the availability of multiple low-cost versions of these drugs have had a significant impact on generic prescription volumes, which rose from 48 to 57.3 percent during the same period and is likely to increase further to 77.6 percent by 2013,” notes Frost & Sullivan Research Analyst Barath Shankar S.

Generic prescription volumes have consistently exceeded those of branded prescriptions and this trend is likely to continue during and beyond the forecast period (2007-2013). A rapidly aging population in the United States is another key reason for the growth of generic prescriptions.

With the demand for generic drugs, increasing, competition in the generic pharmaceuticals market has intensified and sparked off a wave of consolidation. It has also resulted in significant pricing pressures, forcing several generic pharmaceutical companies to sell products at a loss to maintain a broad portfolio of products to improve marketability.

Companies are also looking to diversify their portfolios by manufacturing ‘branded’ generics, which are branded prescription products typically manufactured by small- and medium-sized enterprises. Essentially, ‘branded’ generics are generics in branded packaging, as distinct from ‘authorized generics’ that are branded products with generics packaging. Several generic pharmaceutical companies are using the strategy of diversifying into the branded drug business to ensure greater stability through a steady revenue stream.

Some of the larger companies are considering other strategies such as backward vertical integration into active pharmaceutical ingredients (API) manufacturing from low-cost manufacturing locations. Having a strong API backbone not only ensures steady supply of raw materials for captive consumption, but could also develop into a successful business unit by itself and contribute significantly to the growth of the company.

Given that low-cost manufacturing locations account for the bulk of API supply, companies that implement this strategy will gain an advantage in the competitive and price-driven generic pharmaceuticals market. However, this may not be a feasible strategy for smaller companies due to the high costs involved in acquiring manufacturing plants.

U.S. Generic Pharmaceuticals Market Outlook is part of the Pharmaceutical Growth Partnership Service, which also includes research in the following markets: U.S. opioid and non-opioid pain management pharmaceuticals, analysis of top 10 specialty pharmaceutical companies, and U.S. drug discovery contract research organizations. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Patent Expiry of Blockbuster Drugs and Push for Lower Healthcare Costs Drive Generic Pharmaceuticals Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  Intrinsic Executive Search Ltd

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today